The Filing Desk

Akebia Therapeutics vs Amarin

Akebia Therapeutics AKBA · Amarin AMRN · Pharmaceuticals

Akebia Therapeutics reported revenue of $236 million in fiscal 2025, about the same as Amarin's $214 million in fiscal 2025. Akebia Therapeutics' revenue grew 47.5% in its latest year, and Amarin's fell 6.5%. Akebia Therapeutics had an operating margin of 9.9%, against -23.5% at Amarin.

Side by side

Akebia TherapeuticsAmarin
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$236M$214M
Revenue growth47.5%−6.5%
Revenue growth a year, last 5 years−4.3%−19.0%
Gross margin83.3%56.6%
Operating margin9.9%−23.5%
Net margin−2.3%−18.2%
Free cash flow$68M—
Free cash flow margin28.7%—
Return on capital——
Net debt to EBITDA−5.5x—
Dividends and buybacks$0M$0M
Change in diluted share count21.9%1.0%
Last close$0.42$11.26
P/E at the last close——
Insider trades, last 12 monthsbought $86,588, sold $962,955—
Piotroski F-score7 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Akebia TherapeuticsAmarin
Operating margin
Percent of revenue
Akebia TherapeuticsAmarin
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Akebia TherapeuticsAmarin

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Akebia Therapeutics and Amarin pages.